Canaccord raised the firm’s price target on Ventyx Biosciences (VTYX) to $16 from $14 and keeps a Buy rating on the shares. The firm said the target increase is associated with reduced near-term OpEx projections based on the company’s latest financial results as well as the clinical development status with less clinical trials currently ongoing, compared to 1Q and 2Q25.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VTYX:
- Ventyx Biosciences Reports Q3 2025 Financial Results
- Ventyx Biosciences reports Q3 EPS (32c), consensus (45c)
- Ventyx Biosciences upgraded to Buy from Neutral at H.C. Wainwright
- Ventyx Biosciences price target raised to $14 from $9 at Oppenheimer
- Promising Phase II Trial Results of VTX3232 Bolster Buy Rating for Ventyx Biosciences